

Learner Notification

MED Learning Group

New Developments in the Diagnosis and Management of Chronic Obstructive Pulmonary Disease

March 1, 2024 – March 1, 2025

Online

Acknowledgement of Financial Commercial Support

Regeneron Pharmaceuticals, Inc.

Acknowledgement of In-Kind Commercial Support

No in-kind commercial support was received for this educational activity.

Satisfactory Completion

Learners must listen to each self-directed audio recording while following along with the visual slides and complete an evaluation form to receive a certificate of completion. Your chosen sessions must be viewed in their entirety. Partial credit of individual sessions is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.

Joint Accreditation Statement



JOINTLY ACCREDITED PROVIDER™
INTERPROFESSIONAL CONTINUING EDUCATION

In support of improving patient care, this activity has been planned and implemented by Amedco LLC and MED Learning Group. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Nurses (ANCC) Credit Designation

Amedco LLC designates this activity for a maximum of 1.00 ANCC contact hours.

Objectives - After Attending This Program You Should Be Able To

1. Facilitate a timely and accurate diagnosis of COPD using novel diagnostic methods.
2. Evaluate the roles of the interleukin (IL)-4/13 and IL-33 signaling pathways in the pathophysiology of COPD.
3. Assess data from studies investigating the clinical profiles of emerging therapies for the treatment of COPD.

Disclosure of Conflict of Interest

The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco. All of these relationships were treated as a conflict of interest, and have been resolved. (C7 SCS 6.1---6.2, 6.5)

All individuals in a position to control the content of CE are listed below.

First Name	Last Name	Commercial Interest: Relationship
Russie	Allen	NA
Matthew	Frese	NA
Christina	Gallo	NA
Nicola A.	Hanania	AstraZeneca, GSK, Boehringer Ingelheim, Sanofi/Regeneron, Genentech: Consulting Fees; National Heart, Lung, and Blood Institute (NHLBI), American Lung Association (ALA), GSK, Boehringer Ingelheim, AstraZeneca, Genentech, and Sanofi: Research and Grant Funding
Amanda	Jenkins	NA
Melissa	Johnson	NA
Tara	Mayfield	NA
Jo	Shultz	NA
Lauren	Welch	NA

Questions? Email Certificate@AmedcoEmail.com